🎉 M&A multiples are live!
Check it out!

LakeShore Biopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for LakeShore Biopharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

LakeShore Biopharma Overview

About LakeShore Biopharma

LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.


Founded

2020

HQ

United States of America
Employees

758

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$77.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

LakeShore Biopharma Financials

LakeShore Biopharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, LakeShore Biopharma achieved revenue of $573M and an EBITDA of -$369M.

LakeShore Biopharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See LakeShore Biopharma valuation multiples based on analyst estimates

LakeShore Biopharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $687M $573M XXX XXX XXX
Gross Profit $386M $534M XXX XXX XXX
Gross Margin 56% 93% XXX XXX XXX
EBITDA -$76.8M -$369M XXX XXX XXX
EBITDA Margin -11% -64% XXX XXX XXX
Net Profit -$106M -$145M XXX XXX XXX
Net Margin -15% -25% XXX XXX XXX
Net Debt $94.6M $117M XXX XXX XXX

Financial data powered by Morningstar, Inc.

LakeShore Biopharma Stock Performance

As of April 15, 2025, LakeShore Biopharma's stock price is $2.

LakeShore Biopharma has current market cap of $33.6M, and EV of $77.3M.

See LakeShore Biopharma trading valuation data

LakeShore Biopharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$77.3M $33.6M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

LakeShore Biopharma Valuation Multiples

As of April 15, 2025, LakeShore Biopharma has market cap of $33.6M and EV of $77.3M.

LakeShore Biopharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate LakeShore Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for LakeShore Biopharma and 10K+ public comps

LakeShore Biopharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $77.3M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get LakeShore Biopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

LakeShore Biopharma Valuation Multiples

LakeShore Biopharma's NTM/LTM revenue growth is n/a

LakeShore Biopharma's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $1.0M for the same period.

Over next 12 months, LakeShore Biopharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate LakeShore Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for LakeShore Biopharma and other 10K+ public comps

LakeShore Biopharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -17% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 380% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.8M XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue 49% XXX XXX XXX XXX
G&A Expenses to Revenue 26% XXX XXX XXX XXX
R&D Expenses to Revenue 53% XXX XXX XXX XXX
Opex to Revenue 126% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

LakeShore Biopharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

LakeShore Biopharma M&A and Investment Activity

LakeShore Biopharma acquired  XXX companies to date.

Last acquisition by LakeShore Biopharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . LakeShore Biopharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by LakeShore Biopharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About LakeShore Biopharma

When was LakeShore Biopharma founded? LakeShore Biopharma was founded in 2020.
Where is LakeShore Biopharma headquartered? LakeShore Biopharma is headquartered in United States of America.
How many employees does LakeShore Biopharma have? As of today, LakeShore Biopharma has 758 employees.
Who is the CEO of LakeShore Biopharma? LakeShore Biopharma's CEO is Mr. Xu Wang.
Is LakeShore Biopharma publicy listed? Yes, LakeShore Biopharma is a public company listed on NAS.
What is the stock symbol of LakeShore Biopharma? LakeShore Biopharma trades under LSB ticker.
When did LakeShore Biopharma go public? LakeShore Biopharma went public in 2023.
Who are competitors of LakeShore Biopharma? Similar companies to LakeShore Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of LakeShore Biopharma? LakeShore Biopharma's current market cap is $33.6M
What is the current revenue growth of LakeShore Biopharma? LakeShore Biopharma revenue growth between 2023 and 2024 was -17%.
Is LakeShore Biopharma profitable? Yes, LakeShore Biopharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.